Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

ClinicalTrials.gov ID: NCT04719832

Public ClinicalTrials.gov record NCT04719832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype

Study identification

NCT ID
NCT04719832
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
395 participants

Conditions and interventions

Conditions

Interventions

  • GSK3511294 (Depemokimab) Biological
  • Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 16, 2021
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Last update posted
Dec 16, 2024

2021 – 2023

United States locations

U.S. sites
30
U.S. states
11
U.S. cities
28
Facility City State ZIP Site status
GSK Investigational Site Encinitas California 92024
GSK Investigational Site Long Beach California 90806
GSK Investigational Site Pasadena California 91105
GSK Investigational Site Rancho Cucamonga California 91730
GSK Investigational Site San Jose California 95117
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Loxahatchee Groves Florida 33470-9272
GSK Investigational Site Miami Florida 33125
GSK Investigational Site Miami Florida 33144
GSK Investigational Site New Port Richey Florida 34655
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Alpharetta Georgia 30022
GSK Investigational Site Calhoun Georgia 30103
GSK Investigational Site Columbus Georgia 31326
GSK Investigational Site Savannah Georgia 31406
GSK Investigational Site Normal Illinois 61761
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Owensboro Kentucky 42301
GSK Investigational Site Rochester Hills Michigan 48507
GSK Investigational Site Las Vegas Nevada 89123
GSK Investigational Site New York New York 10036
GSK Investigational Site The Bronx New York 10459-2417
GSK Investigational Site Gastonia North Carolina 28054
GSK Investigational Site Cleveland Ohio 44106
GSK Investigational Site Boerne Texas 78006
GSK Investigational Site Cypress Texas 77099
GSK Investigational Site Cypress Texas 77429
GSK Investigational Site Dallas Texas 75235
GSK Investigational Site Kerrville Texas 78028
GSK Investigational Site San Antonio Texas 78258

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04719832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2024 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04719832 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →